Life Science REIT plc
(the "Company")
LEI: 213800RG7JNX7K8F7525
3 June 2025
Annual General Meeting ("AGM") Results
The Company announces that at its Annual General Meeting held earlier today all the resolutions set out in the Notice of Annual General Meeting were passed. All resolutions were voted on by way of a poll. The results of the poll for each resolution were as follows:
|
Resolution
| For | Against
|
Votes Withheld (No. of shares)
| ||
| No. of shares |
%
| No. of shares | % | ||
|
1. To receive and approve the annual report and financial statements
| 170,107,273
| 99.00%
| 1,725,065
| 1.00%
| 73,670
|
| 2. To receive and approve the Directors' remuneration report | 170,955,999
| 99.53%
| 803,872
| 0.47%
| 146,137
|
| 3. To approve the Directors' remuneration policy | 170,735,896
| 99.40%
| 1,025,053
| 0.60%
| 145,059
|
| 4. To approve the Company's dividend payment policy |
171,288,518
| 99.70%
| 509,154
| 0.30%
| 108,336
|
| 5. To re-elect Claire Boyle as a Director of the Company |
162,069,299
| 94.32%
| 9,756,368
| 5.68%
| 80,341
|
| 6. To re-elect Mike Taylor as a Director of the Company |
168,458,021
| 98.04%
| 3,367,646
| 1.96%
| 80,341
|
| 7. To re-elect Richard Howell as a Director of the Company |
168,458,021
| 98.04%
| 3,367,646
| 1.96%
| 80,341
|
| 8. To re-elect Sally Ann Forsyth as a Director of the Company |
160,401,176
| 93.35%
| 11,424,491
| 6.65%
| 80,341
|
|
9. To re-appoint Deloitte LLP as Auditor to the Company
| 171,653,308
| 99.90%
| 179,030
| 0.10%
| 73,670
|
|
10. To authorise the Audit and Risk Committee to determine the remuneration of the Auditor to the Company
|
171,676,363
|
99.92%
|
132,968
|
0.08%
|
96,677
|
| 11. To authorise the Directors to allot equity securities |
154,506,973
| 93.03%
| 11,569,169
| 6.97%
| 5,829,866
|
|
12. To authorise the Directors to disapply pre-emption rights*
| 144,015,864
| 86.72%
| 22,060,278
| 13.28%
| 5,829,866
|
|
13. To authorise the Directors to disapply pre-emption rights for the purposes of financing an acquisition or other capital investment*
| 143,882,140
| 86.70%
| 22,067,565
| 13.30%
| 5,956,303
|
|
14. To approve the purchase of the Company's own shares*
| 167,087,012
|
97.24%
| 4,745,326
| 2.76%
| 73,670
|
| 15. That a general meeting, other than an AGM, may be called on not less than 14 clear days' notice* | 168,132,129
| 97.85%
| 3,700,209
| 2.15%
| 73,670
|
*special resolution
| NOTES:
| |
| 1. | All resolutions were passed.
|
| 2.
| Percentages have been rounded to two decimal places. |
| 3. | Proxy appointments which gave discretion to the Chair of the AGM have been included in the "For" total for the appropriate resolution.
|
| 4. | Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
|
| 5. | A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
|
| 6. | The number of shares in issue at 10:00 am. on 30 May 2025 was 350,000,000 ordinary shares, carrying one vote each, and at that time, the Company did not hold any shares in treasury.
|
| 7. | The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at https://lifesciencereit.co.uk/investors/shareholder-information/
|
Enquiries:
| MUFG Corporate Governance Limited - Company Secretary |
|
| labs_cosec@cm.mpms.mufg.com |
|
|
|
|
| Ironstone Asset Management - Investment Adviser |
|
| Simon Farnsworth/ Joanna Waddingham | via FTI Consulting below |
|
|
|
| Panmure Liberum - Financial Adviser & Corporate Broker | +44 20 7886 2500 |
| Alex Collins / Tom Scrivens | |
| G10 Capital Limited - AIFM | +44 20 7397 5450 |
| Verity Morgan-Jones / Maria Baldwin | |
|
FTI Consulting - PR Adviser |
+44 20 3727 1000 |
| Dido Laurimore / Richard Gotla / Oliver Parsons | |
| LifeScienceReit@fticonsulting.com | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.